Table 1.
Clinical data used in CPI population PBPK model development
| No. subjects | Study 1 (Shen et al. 2019) 37 | Study 2 (Yee et al. 2019) 25 | Study 3 (Lai et al. 2019) 24 | |
|---|---|---|---|---|
| 14 | 8 | 8 | 12 | |
| Ethnicity | Asian‐Indians | Caucasian | Caucasian | Asian‐Indians |
| Sex | Male | Male | Female | Male |
| Study duration | 24h | 12h | 12h | 24h |
| SLCO1B1 c.521 Genotype | TT (n = 13), TC (n = 1) | TT (n = 4), TC (n = 3), CC (n = 1) | TT (n = 4), TC (n = 3), CC (n = 1) | TT (n = 12) |
| No. occasions; treatment |
Occ 1; Predose Occ 2; Furosemide |
Occ 1; Pravastatin | Occ 1; Pravastatin |
Occ 1; Rifampicin, Occ 2; Rosuvastatin Occ 3; Rifampicin + Rosuvastatin |
| No. plasma samples |
Occ 1; 155 (TT) and 12 (TC) Occ 2; 151 (TT) and 11 (TC) |
(TT); 58 (TC); 44 (CC); 15 |
(TT); 57 (TC); 41 (CC); 14 |
Occ 1; 144 Occ 2; 132 Occ 3; 132 |
| No. urine samples | 0 | 0 | 0 |
34 (pre‐treatment) 68 (post‐treatment) |
| Cave,base, nM |
TT; 1.07 ± 0.26 TC; 1.86 |
TT; 0.66 ± 0.11 TC; 1.08 ± 0.14 CC; 1.74 |
TT; 0.54 ± 0.05 TC; 0.69 ± 0.13 CC; 1.37 |
TT; 0.87 ± 0.16 |
Cave,base, coproporphyrin I concentration in plasma over whole study period in occasions without rifampicin treatment; CPI, coproporphyrin I; Occ, occasion.